SCHEMBL4498140

SCHEMBL4498140

CC(C)[C@H](N)CNc1nc(-c2ccccc2O)nc2ccccc12

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 12/20 0.62
KMT2A Q03164 12/20 0.62
RXFP1 Q9HBX9 2/20 0.62
MAPT P10636 9/20 0.60
HIF1A Q16665 2/20 0.56
NPSR1 Q6W5P4 3/20 0.55
EGFR P00533 1/20 0.55
PKM P14618 1/20 0.55
ALK Q9UM73 2/20 0.54
ACP1 P24666 1/20 0.53
POLB P06746 3/20 0.53
GAA P10253 2/20 0.53
NTRK1 P04629 1/20 0.53
PIP4K2A P48426 1/20 0.53
LMNA P02545 2/20 0.52
HCRTR1 O43613 1/20 0.52
ALDH1A1 P00352 1/20 0.52
MAPK1 P28482 1/20 0.52
CASP1 P29466 1/20 0.52
SMN1; SMN2 Q16637 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4498146 1.00 MEN1 (0.62) MEN1KMT2ARXFP1MAPTHIF1A
SCHEMBL4498147 1.00 MEN1 (0.62) MEN1KMT2ARXFP1MAPTHIF1A
SCHEMBL4519839 0.92 MEN1 (0.61) MEN1KMT2ARXFP1MAPTHIF1A
SCHEMBL3907257 0.90 MEN1 (0.65) MEN1KMT2ARXFP1MAPTHIF1A
SCHEMBL4501723 0.90 MEN1 (0.65) MEN1KMT2ARXFP1MAPTHIF1A
SCHEMBL3907263 0.90 MEN1 (0.65) MEN1KMT2ARXFP1MAPTHIF1A
SCHEMBL4501222 0.89 ALK (0.50) MEN1KMT2ARXFP1MAPTHIF1A
SCHEMBL4501225 0.89 ALK (0.50) MEN1KMT2ARXFP1MAPTHIF1A
SCHEMBL4501217 0.89 ALK (0.50) MEN1KMT2ARXFP1MAPTHIF1A
SCHEMBL4503401 0.88 ACP1 (0.51) MEN1KMT2ARXFP1MAPTHIF1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090247519-A1 AMINO-ETHYL-AMINO-ARYL (AEAA) COMPOUNDS AND THEIR USE CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2009-10-01 US disclosed
US-20090247519-A1 AMINO-ETHYL-AMINO-ARYL (AEAA) COMPOUNDS AND THEIR USE CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2009-10-01 US disclosed
US-20090247519-A1 AMINO-ETHYL-AMINO-ARYL (AEAA) COMPOUNDS AND THEIR USE CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2009-10-01 US disclosed
WO-2007125331-A2 AMINO-ETHYL-AMINO-ARYL (AEAA) COMPOUNDS AND THEIR USE CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2007-11-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090247519-A1 AMINO-ETHYL-AMINO-ARYL (AEAA) COMPOUNDS AND THEIR USE PKD2, PKD1, AADAT MEN1 4237/4885KMT2A 230/4885RXFP1 3771/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.